WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic and Inflammation Research

Executive Summary: WY-14643, also known as Pirinixic Acid, is a highly selective and potent peroxisome proliferator-activated receptor alpha (PPARα) agonist with an IC₅₀ of 10.11 µM for human PPARα (APExBIO, product page). Dual PPARα/γ agonism is achieved via aliphatic α-substitution, expanding its utility to broader metabolic research [see comparative analysis]. WY-14643 modulates hepatic TNFα mRNA and VCAM-1, demonstrating anti-inflammatory and insulin-sensitizing effects in preclinical models (Bao et al., 2025). It is insoluble in water but dissolves in DMSO and ethanol, supporting diverse workflow integration. This article details its biological rationale, molecular mechanism, validated benchmarks, and corrects common misconceptions.

Biological Rationale

PPARα is a nuclear receptor central to lipid metabolism and inflammation control. Agonists like WY-14643 enable precise dissection of PPARα-regulated gene networks, with particular relevance to metabolic syndrome, NAFLD, and vascular inflammation. Studies reveal that activation of PPARα by ligands such as WY-14643 mediates transcriptional changes in genes governing fatty acid β-oxidation, lipoprotein assembly, and cytokine production (Bao et al., 2025). In pulmonary lymphoepithelioma-like carcinoma (pLELC), PPARα signaling has been implicated in tumor microenvironment modulation through upregulation of tissue factor (TF) and downstream leukocyte migration pathways. These insights underscore the translational impact of selective PPARα agonists in both metabolic and oncologic research.

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds PPARα with high affinity (IC₅₀ = 10.11 µM) and promotes its heterodimerization with RXR (retinoid X receptor). The complex translocates to PPAR response elements (PPREs) in DNA, activating transcription of target genes involved in lipid transport, β-oxidation, and anti-inflammatory response (APExBIO). Aliphatic α-substitution in the WY-14643 scaffold enhances dual agonist activity for both PPARα and PPARγ, supporting the development of balanced modulators with micromolar potency. In endothelial cells, WY-14643 pretreatment at 250 μM down-regulates TNF-α-induced VCAM-1 expression and reduces monocyte adhesion, evidencing direct anti-inflammatory action (Bao et al., 2025). Kupffer cell activation by WY-14643 leads to moderate elevation of hepatic TNFα mRNA, indirectly stimulating hepatocyte mitogenesis. This mechanism links metabolic reprogramming to tissue regeneration and inflammation control.

Evidence & Benchmarks

• WY-14643 acts as a potent and selective PPARα agonist (IC₅₀ = 10.11 µM, human PPARα) (APExBIO, product).
• Aliphatic α-substitution enhances dual PPARα/γ agonism, with balanced activity in the low micromolar range (benchmarking study).
• Pretreatment with 250 μM WY-14643 in endothelial cells significantly down-regulates TNF-α-induced VCAM-1 and reduces monocyte adhesion, confirming anti-inflammatory efficacy (Bao et al., 2025, Fig. 4).
• In high fat-fed rat models, oral WY-14643 at 3 mg/kg/day for 2 weeks lowers plasma glucose, triglycerides, leptin, muscle triglycerides, and long-chain acyl-CoAs, reduces visceral fat and hepatic lipids, and enhances whole-body insulin sensitivity without affecting body weight (APExBIO, datasheet).
• In pLELC, linoleic acid-induced TF upregulation is mediated by PPARα, and this axis can be targeted for microenvironmental reprogramming (Bao et al., 2025, Abstract/Results).

This article extends the mechanistic coverage provided in [this review] by integrating new multiomics evidence from recent pLELC models and translational metabolic studies. For a focused discussion on dual PPARα/γ activity, see [this in-depth analysis]; the present article updates its claims with new anti-inflammatory benchmarks and improved workflow recommendations.

Applications, Limits & Misconceptions

WY-14643 is widely used in:

• Metabolic disorder research: Dissecting lipid metabolism, insulin sensitivity, and hepatic steatosis.
• Vascular inflammation models: Evaluating TNF-α mediated endothelial activation and leukocyte adhesion.
• Tumor microenvironment modulation: Targeting PPARα-driven TF expression and immune infiltration in pLELC (Bao et al., 2025).
• Translational screening: Benchmarking dual PPARα/γ modulators in advanced metabolic and immunometabolic workflows.

However, certain boundaries and misconceptions are notable.

Common Pitfalls or Misconceptions

• WY-14643 is not a pan-PPAR agonist; it is selective for PPARα and only achieves dual PPARα/γ activity with specific α-substitution.
• The compound is intended strictly for research use; it is not approved for diagnostic or therapeutic applications in humans.
• Water insolubility requires the use of DMSO or ethanol (with ultrasonic assistance) for solution preparation; incorrect solvents may yield precipitation and assay artifacts.
• Anti-inflammatory effects are context-dependent and may not translate across all cell types or disease models; results should be interpreted with reference to specific experimental conditions.
• Hepatic TNFα upregulation is moderate and indirect; WY-14643 does not directly activate pro-inflammatory cytokine cascades in hepatocytes.

Workflow Integration & Parameters

WY-14643 (APExBIO SKU: A4305) is supplied as a solid, water-insoluble powder. It is soluble in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL with ultrasonic assistance). Storage at -20°C is recommended; prepared solutions should be used within a short-term window to avoid degradation (APExBIO). For in vitro studies, concentrations of 10–250 μM are typical, with 250 μM used for robust anti-inflammatory testing in endothelial cells. In animal studies, oral dosing at 3 mg/kg/day x 14 days in high fat-fed rats is validated for metabolic endpoint analysis. Aqueous buffer systems should be pre-tested for solubility to avoid precipitation. For an updated protocol guide, refer to the workflow article, which addresses solubilization and dosing; this present summary integrates latest evidence for solution stability and experimental endpoints.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) is a cornerstone reagent for dissecting the PPAR signaling pathway in metabolic, inflammatory, and oncologic models. Its selectivity, validated benchmarks, and robust translational performance make it indispensable for advanced research. As multiomics evidence accumulates, WY-14643 will continue to clarify PPAR-mediated mechanisms in disease and regeneration. For procurement and technical support, refer to the official APExBIO product page.